Literature DB >> 34918301

Xenograft Models of Ovarian Cancer for Therapy Evaluation.

Mihaela Popa1, Vibeke Fosse1, Katrin Kleinmanns1, Line Bjørge1,2, Emmet McCormack3.   

Abstract

The evaluation of novel treatment regimes in ovarian cancer, ranging from cytotoxic agents and targeted therapy to surgery, demands clinically relevant mouse models to mimic human disease. These more advanced preclinical models provide a tool to obtain robust data on the mechanism of action, cytotoxicity and therapeutic efficacy of newly emerging antitumor therapies.In this chapter, we describe how to generate ovarian cancer xenograft models through injection of human tumor cell lines in immunocompromised mice. Detailed methodological descriptions are provided for both the commonly applied subcutaneous model and the more technically challenging orthotopic tumor model that involves inoculation of cancer cells in the ovarian bursa. We demonstrate how to monitor tumor growth and metastases in orthotopic ovarian models through noninvasive optical imaging and the procedures for treatment strategy, including administration of test compounds and debulking surgery. We comment on the strengths, limitations, and procedural challenges associated with each of the models.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Imaging; Mouse models; Orthotopic; Ovarian cancer; Ovariohysterectomy; Preclinical drug evaluation; Subcutaneous; Xenograft models

Mesh:

Year:  2022        PMID: 34918301     DOI: 10.1007/978-1-0716-1956-8_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes.

Authors:  Maria Grazia Perrone; Paola Vitale; Morena Miciaccia; Savina Ferorelli; Antonella Centonze; Roberta Solidoro; Cristina Munzone; Carmela Bonaccorso; Cosimo Gianluca Fortuna; Katrin Kleinmanns; Line Bjørge; Antonio Scilimati
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-26

2.  PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression via ROS/Wnt/β-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib.

Authors:  Xiaocui Zhang; Meige Sun; Yisheng Jiao; Bei Lin; Qing Yang
Journal:  Oxid Med Cell Longev       Date:  2022-09-05       Impact factor: 7.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.